These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23600973)

  • 1. Reduction of prostate cancer incidence by naftopidil, an α1 -adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
    Yamada D; Nishimatsu H; Kumano S; Hirano Y; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Kume H; Homma Y
    Int J Urol; 2013 Dec; 20(12):1220-7. PubMed ID: 23600973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial comment from Dr Murtola to reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
    Murtola TJ
    Int J Urol; 2013 Dec; 20(12):1227-8. PubMed ID: 23600459
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial comment from Dr Chen to reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
    Chen IJ
    Int J Urol; 2013 Dec; 20(12):1227. PubMed ID: 23600404
    [No Abstract]   [Full Text] [Related]  

  • 4. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma.
    Hori Y; Ishii K; Kanda H; Iwamoto Y; Nishikawa K; Soga N; Kise H; Arima K; Sugimura Y
    Cancer Prev Res (Phila); 2011 Jan; 4(1):87-96. PubMed ID: 21205739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
    Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naftopidil induces apoptosis in malignant mesothelioma cell lines independently of α1-adrenoceptor blocking.
    Masachika E; Kanno T; Nakano T; Gotoh A; Nishizaki T
    Anticancer Res; 2013 Mar; 33(3):887-94. PubMed ID: 23482758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest.
    Kanda H; Ishii K; Ogura Y; Imamura T; Kanai M; Arima K; Sugimura Y
    Int J Cancer; 2008 Jan; 122(2):444-51. PubMed ID: 17918159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia.
    Kojima Y; Sasaki S; Oda N; Koshimizu TA; Hayashi Y; Kiniwa M; Tsujimoto G; Kohri K
    Prostate; 2009 Oct; 69(14):1521-8. PubMed ID: 19544328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
    Keledjian K; Kyprianou N
    J Urol; 2003 Mar; 169(3):1150-6. PubMed ID: 12576871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia.
    Kojima Y; Sasaki S; Kubota Y; Hayase M; Hayashi Y; Shinoura H; Tsujimoto G; Kohri K
    J Urol; 2008 Mar; 179(3):1040-6. PubMed ID: 18206918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel naftopidil-related derivatives and their biological effects as alpha1-adrenoceptors antagonists and antiproliferative agents.
    Huang J; He F; Huang M; Liu X; Xiong Y; Huang Y; Zhu L; Yang Y; Xu X; Yuan M
    Eur J Med Chem; 2015; 96():83-91. PubMed ID: 25874333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study.
    Harris AM; Warner BW; Wilson JM; Becker A; Rowland RG; Conner W; Lane M; Kimbler K; Durbin EB; Baron AT; Kyprianou N
    J Urol; 2007 Nov; 178(5):2176-80. PubMed ID: 17870114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor action of α(1)-adrenoceptor blockers on human bladder, prostate and renal cancer cells.
    Gotoh A; Nagaya H; Kanno T; Nishizaki T
    Pharmacology; 2012; 90(5-6):242-6. PubMed ID: 23007551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines.
    Forbes A; Anoopkumar-Dukie S; Chess-Williams R; McDermott C
    Prostate; 2016 Jun; 76(8):757-66. PubMed ID: 26880388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
    Masumori N; Tsukamoto T; Iwasawa A; Furuya R; Sonoda T; Mori M;
    Urol Int; 2009; 83(1):49-54. PubMed ID: 19641359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
    Kyprianou N; Benning CM
    Cancer Res; 2000 Aug; 60(16):4550-5. PubMed ID: 10969806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors.
    Takei R; Ikegaki I; Shibata K; Tsujimoto G; Asano T
    Jpn J Pharmacol; 1999 Apr; 79(4):447-54. PubMed ID: 10361884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
    Benning CM; Kyprianou N
    Cancer Res; 2002 Jan; 62(2):597-602. PubMed ID: 11809715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Repositioning of the α
    Florent R; Poulain L; N'Diaye M
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32727149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.